Résumé
Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results.
Sujets)
Humains , Pronostic , Pyrimidines/usage thérapeutique , Résistance aux substances , Leucémie myéloïde chronique BCR-ABL positive/traitement médicamenteux , Surveillance des médicaments , Récepteurs à activité tyrosine kinase , Résistance aux médicaments antinéoplasiques , Surveillance de l'environnement , Mésilate d'imatinib , Antinéoplasiques/administration et posologieRésumé
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.